Related Experiment Video
Updated: Mar 30, 2026
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both
Sripal Bangalore1, Rana Fayyad2, John J Kastelein3
1New York University School of Medicine, New York, NY.
Insights
Percent low-density lipoprotein cholesterol (LDL-C) reduction, not the attained LDL-C level, provides significant prognostic value in patients with atherosclerotic cardiovascular disease treated with statins.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- The 2013 ACC/AHA cholesterol guidelines recommend statins for atherosclerotic cardiovascular disease (ASCVD) but moved away from treat-to-target.
- The incremental prognostic value of LDL-C reduction percentage versus attained LDL-C levels alongside statin dose is unknown.
Purpose of the Study:
- To determine if percent LDL-C reduction or attained LDL-C levels add prognostic value beyond statin dose in ASCVD patients.
Main Methods:
- Analysis of patient-level data from TNT, IDEAL, and SPARCL trials involving statin treatment.
- Patients categorized by attained LDL-C (≤70 vs >70 mg/dL) and percent LDL-C reduction (≥50% vs <50%).
- Cox proportional hazards models assessed incremental prognostic value of statin dose, attained LDL-C, and percent LDL-C reduction.
Main Results:
- Percent LDL-C reduction significantly added prognostic value over statin dose and attained LDL-C levels.
- Attained LDL-C levels did not provide additional prognostic value beyond statin dose and percent LDL-C reduction.
- Patients with <50% LDL-C reduction had higher risks of major cardiovascular events and stroke, even with attained LDL-C ≤70 mg/dL.
Conclusions:
- In ASCVD patients on statins, percent LDL-C reduction is a crucial prognostic indicator.
- Attained LDL-C levels do not offer additional prognostic information beyond statin dose and reduction percentage.
Background:
The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the treatment of blood cholesterol recommends moderate- to high-intensity statins for patients with atherosclerotic cardiovascular disease but departs from the traditional treat-to-target approach. Whether percent low-density lipoprotein cholesterol (LDL-C) reduction or attained LDL-C levels add incremental prognostic value to statin dose is not known.
Methods:
Patients in the Treating to New Targets (TNT), Incremental Decrease in Endpoints through Aggressive Lipid Lowering (IDEAL), and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trials (patient-level data) randomized to a statin arm (atorvastatin 80 mg/10 mg or simvastatin 20 mg) were chosen. Patients were divided into groups based on attained LDL-C levels (≤70 vs >70 mg/dL) and percent LDL-C reduction (≥50% vs <50%). Primary outcome was major cardiovascular event defined as death due to coronary heart disease, nonfatal myocardial infarction, resuscitated cardiac arrest, or stroke. Incremental prognostic value was assessed by using a forward conditional Cox proportional hazards model. Two models were tested: Model 1: Step 1 statin dose; Step 2 add attained LDL-C levels (continuous variable); Step 3 add percent LDL-C reduction (continuous variable). Model 2: Steps 2 and 3 were reversed.
Results:
Among 13,937 patients included in this study, percent LDL-C reduction added incremental prognostic value over both statin dose and attained LDL-C levels (global chi-square increased from 3.64 to 26.1 to 47.5; P <.0001). However, attained LDL-C level did not provide incremental prognostic value over statin dose and percent LDL-C reduction (global chi-square increased from 3.64 to 47.5 to 47.5; P <.0001 and .94, respectively). Among patients with attained LDL-C ≤70 mg/dL, those with percent LDL-C reduction of <50% had a significantly higher risk of primary outcome (hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.16-1.97; P = .002) and stroke (HR, 2.07; 95% CI, 1.46-2.93; P <.0001) and a numerically higher risk of death (HR, 1.37; 95% CI, 0.98-1.90; P = .06) when compared with the group with percent LDL-C reduction of ≥50%.
Conclusions:
In patients with atherosclerotic cardiovascular disease, percent LDL-C reduction provides incremental prognostic value over statin dose and attained LDL-C levels. However, the attained LDL-C level does not provide additional prognostic value over statin dose and percent LDL-C reduction.
More Related Videos
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Related Concept Videos
01:26Atherosclerosis III: Management
01:18Lipids: Dietary Sources and Requirements
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Coronary Artery Disease IV: Preventive Measures
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents